Primary immunodeficiency disease (PIDD) comprises a group of more than 450 inborn errors of immunity, which can leave patients at risk for severe infection, increased susceptibility to burdensome clinical manifestations, and lifelong impairment. PIDD can appear at any age, but the more severe forms of disease are usually seen in infancy or early childhood. Thus, pediatric clinicians are in a unique position to recognize and manage PIDD in patients presenting with unusual and/or recurrent infections. Earlier recognition is critical, as the time between symptom onset to diagnosis of PIDD takes an average of 12 years in the United States, exposing patients to multiple infections, health deterioration, organ damage, and increased mortality. Fortunately, with appropriate treatment, patients can ultimately lead normal and productive lives.
In this CME Outfitters recorded symposium, expert faculty discuss pediatric patient cases that illustrate the timely assessment of telltale signs and symptoms indicative of an underlying immunologic deficiency. A multidisciplinary approach to management is explored, including when to refer, the role of evidence-based treatments, and long-term monitoring.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, physician associates (PAs), nurse practitioners (NPs), and pharmacists specializing in pediatrics.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Paris reports the following financial relationships: Advisory Board: KORU Medical Systems and Takeda Pharmaceuticals U.S.A., Inc. Consultant: Grifols; Research Support and Speakers Bureau: Takeda Pharmaceuticals U.S.A., Inc.
Dr. Chong reports the following financial relationships: Consultant: Horizon Therapeutics; Parexel International Corporation; and PRECISIONscientia.
Ms. Epland reports the following financial relationships: Advisory Board: Immune Deficiency Foundation Nurse Advisory Committee-member; Consultant: Takeda Pharmaceuticals U.S.A., Inc. Speakers Bureau: Takeda Pharmaceuticals U.S.A., Inc. (Nurses Speakers Bureau)
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).